GLOW: Global nLPHL One Working Group

Announcing the International Prognostic Score for NLPHL (LP-IPS) in @JCO_ASCO, the largest study of NLPHL to date. Congratulations to our founders Drs. @michaelsbinkley & @JamieFlerlage and the GLOW team on this high-impact publication. #NLPHLsm #lymsm ascopubs.org/doi/pdf/10.120…

Our @glow_nlphl lead Dr. @JamieFlerlage spoke about the GLOW multicenter study of radiation therapy outcomes for Stage IA NLPHL which she presented at #18ICML for @VJHemOnc. #lymsm #NLPHLsm vjhemonc.com/video/amtyhj8p…

Congratulations to Dr. Juliana Costa on presenting @glow_nlphl at Congreso @ACHOP_COL in Colombia and how to establish NLPHL registries in Latin America. Additional thanks to Drs. Ana Rosa Braz Costa and Adriana Morais for their leadership on this work. #lymsm #NLPHLsm

Proud to work with this incredible group of investigators and patients @glow_nlphl on studying patient-reported outcomes and the patient experience in this rare disease. #18ICML #lymsm

Outcomes Stage IA NLPHL @glow_nlphl: superior PFS (not OS) for RT after complete resection (vs observation). For unresected patients, best PFS with RT & RT+ABVD, no diff OS. No diff in transformation events. More numerical SPMs after RT. #lymsm #18ICML

Resection + RT improves PFS vs observation alone (90% vs 65%) for NLPHL presented by @JamieFlerlage #ICML18 @glow_nlphl

Congratulations to Dr. @JamieFlerlage on her oral presentation at #18ICML on our @glow_nlphl analysis of radiotherapy in Stage IA NLPHL. #lymsm

You can observe advanced-stage NLPHL just like other indolent lymphomas. No compromised PFS2 for patients who are initially observed. And only 1/3 of patients needed treatment. #18ICML #lymsm @glow_nlphl

Transformation not uncommon in NLPHL, more common with Pattern E (I always ask hematopathology to identify pattern) and splenic involvement. #18ICML #lymsm #NLPHLsm

NLPHL session at #18ICML. Fascinating work about association of NLPHL with bacterial infections in patients with certain HLA types. #lymsm #NLPHLsm cc @glow_nlphl

Congratulations to all our @glow_nlphl contributing centers on establishing the first prognostic index specifically for NLPHL. #lymsm #18ICML

We are seeking patients with relapsed or refractory FL or DLBCL for a compensated study about experiences with bispecific antibody therapies. To my #lymsm & #onctwitter colleagues: please share the attached flyer with your networks. Thank you! #tcellrx

To my lymphoma colleagues: we are performing a study of patient experiences with bispecific antibodies for relapsed/refractory DLBCL or FL. Please share this flyer with your patient groups and networks. Thank you! #lymsm

Read the editorial written about our @glow_nlphl research roadmap manuscript in Pediatric Blood & Cancer: onlinelibrary.wiley.com/doi/10.1002/pb… #lymsm #nlphlsm

Our @glow_nlphl research roadmap for NLPHL is now published. In this manuscript, we review the historical research challenges in NLPHL research and progress to date of our international GLOW Consortium (glowconsortium.org). #lymsm #nlphlsm onlinelibrary.wiley.com/doi/epdf/10.10…

"A diagnosis of NLPHL is often a long, confusing, and isolating journey." Our @glow_nlphl study of patient & care partner perspectives on NLPHL, and how we can better counsel on management options. Many thanks to our collaborating patient advocates. #lymsm tandfonline.com/doi/full/10.10…

Announcing our latest @glow_nlphl study, a qualitative analysis of patient & care partner perspectives on treatment decision-making in NLPHL. This study enables investigators to better align NLPHL research with patient priorities. #lymsm #nlphlsm tandfonline.com/doi/full/10.10…

The LP-IPS prognostic score for NLPHL, developed through the @glow_nlphl consortium, was just cited in a new review published by Drs. Eichenauer & Borchmann. #lymsm #NLPHLsm tandfonline.com/doi/full/10.10…

For those interested in clinical trials, there is a trial-in-progress being presented at the @ASH_hematology #ASH24 annual meeting this weekend by Dr. Steiner on rituximab versus mosunetuzumab for either untreated Stage IB-IV NLPHL or relapsed NLPHL of any stage. #lymsm #NLPHLsm

An important scientific workshop this Friday at #ASH24 on germline TET2 mutations predisposing patients to the development of NLPHL. #lymsm #NLPHLsm ash.confex.com/ash/2024/webpr…

New consensus algorithm for the treatment of NLPHL by @graham74GC & @chanyooncheah, now published @Haematologica. Looking forward to the forthcoming @glow_nlphl trial to establish a care standard for Stage I-II NLPHL. @michaelsbinkley @JamieFlerlage #lymsm buff.ly/4fHdP0v